Vildagliptin enhances differentiation of insulin producing cells from adipose-derived mesenchymal stem cells
Cell Journal [Yakhteh]. 2019; 20 (4): 477-482
en Inglés
| IMEMR
| ID: emr-199616
ABSTRACT
Objective:
Type 1 diabetes is caused by destruction of beta cells of pancreas. Vildagliptin [VG], a dipeptidyl peptidase IV [DPP IV] inhibitor, is an anti-diabetic drug, which increases beta cell mass. In the present study, the effects of VG on generation of insulin-producing cells [IPCs] from adipose-derived mesenchymal stem cells [ASCs] is investigated
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Idioma:
Inglés
Revista:
Cell J. [Yakhteh]
Año:
2019
Similares
MEDLINE
...
LILACS
LIS